In retrospective studies performed in the mCRC tumor microenvironment, the introduction of anti-EGFR mAbs with concomitant chemotherapy was linked with higher quantities of cytotoxic CD8+ cells, memory-effector CD45RO+ cells, and regulatory FOXP3+ T cells within metastatic sites compared with scenarios without treatment, with chemotherapy alone, or chemotherapy coupled with antiangiogenic mAbs [87]. Here, EGFR is linked to neoplasm.